/stocks — the workspaceLOADING
All INM SEC filings, by type → · Earnings date & implied move · Search inside filings
INM is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Latest report (10-Q, filed 2026-11-03). Three months to 2026-09-30 against 2025-09-30: Net loss $2.3M, 35.0% larger than $1.7M; Operating cash used $1.1M, 40.8% smaller than $1.9M. Read it line by line, each linked to its source → · Every report →
InMed Pharmaceuticals Inc. (INM) is a pharmaceutical preparations company. Piotroski F-Score 3/8. 7 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind INM’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has INM been issuing shares? Offering history →
Volume against its own history: 87% of its last 252 sessions were lighter than the last one, the 2026-11-06 session. End-of-day bars (Databento). Volume detail
| Diluted EPS | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2026 | -3.12 USD | -8.36 USD | not a growth rate (a year at or below zero) | 10-K filed 2026-09-09 |
| fiscal 2025 | -8.36 USD | -20.14 USD | not a growth rate (a year at or below zero) | 10-K filed 2025-09-23 |
| fiscal 2024 | -1.01 USD | -3.25 USD | not a growth rate (a year at or below zero) | 10-K filed 2024-09-30 |
| fiscal 2023 | -3.25 USD | -33.17 USD | not a growth rate (a year at or below zero) | 10-K filed 2023-09-29 |
| fiscal 2022 | -33.17 USD | -37.96 USD | not a growth rate (a year at or below zero) | 10-K filed 2022-09-23 |
| fiscal 2021 | -1.52 USD | -1.71 USD | not a growth rate (a year at or below zero) | 10-K filed 2021-09-24 |
Concepts read: us-gaap:EarningsPerShareBasicAndDiluted; us-gaap:EarningsPerShareDiluted
Per filed share, as each report states it. Free cash flow per share is operating cash flow less capital expenditure, over the diluted weighted average share count (or net income over diluted EPS where the count is tagged per share class).
Each year’s change comes from one annual report, which states that year and the year before on the same share basis, and the rate compounds those changes; so a split or a restatement between reports cannot bend it. A rate needs a positive figure at both ends of its window. The DCF above grows total free cash flow and divides by today’s share count, so a per-share rate also carries the buybacks or new shares of those years. These are past figures, not a forecast.
Not shown yet: the P/E range INM has traded at, which would set the discount rate and terminal assumptions against its own history. It needs a long daily price history we are not yet licensed to display.
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from INM’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as INM tagged it: revenue us-gaap:Revenues, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on INM plus an auto-SWOT, built from INM's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate INM using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about INM’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
Daily closes from 2024-07-01 through 2026-11-06, 592 sessions, split-adjusted (3 splits applied). No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in INM’s filings; the chart with studies draws every figure.
Written by code from 592 end-of-day bars through 2026-11-06. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
Projected from INM's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentINM files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Nothing on file for INM from Nov 10, 2026 to Nov 23, 2026 in these sources: earnings date and filing deadline.
| Event | Result |
|---|---|
| Earnings date | nothing in the window. No date in the window: no regular report cadence in the filings. |
| Filing deadline | nothing in the window. Nothing in the window: the 10-Q for the quarter ending Dec 31, 2026, due 40 to 45 days after it as SEC states no filer status for it, the span covers every status, falls due between Feb 9, 2027 and Feb 16, 2027, after it. Newest periodic report on file: the 10-Q for the period ending Sep 30, 2026, filed Nov 3, 2026. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-10 to 2026-11-23, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
2 of the 2 checks that ran found nothing new for INM. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
The estimators disagree by 174% of the midpoint. A wide band is itself the finding: this company’s value depends heavily on which yardstick you use, so treat any single number for INM — ours or anyone else’s — with corresponding caution.
The band is the interquartile range of every estimator that could run on INM’s filings: the median P/E, P/S, P/B and P/FCF this stock has actually traded at over 6 years of history applied to today’s fundamentals, a two-stage discounted-cash-flow estimate. With four or more estimators we take the interquartile range, so a single wild reading cannot define the band; with two or three we show the full spread, because trimming the tails off three points does not remove noise, it manufactures confidence. We publish a range rather than one number because the estimators genuinely disagree, and averaging that disagreement away would hide the most useful part.
Valuation labels describe only where the price sits against that band:
These labels are positional, not predictive. Premium means the current share price sits above the band computed from INM’s own filings and trading history. It does not mean the stock cannot keep rising, that a fall is expected, or that the market has it wrong. Equally, Discount means the price sits below that band — it does not imply the stock is cheap in any meaningful sense, that it is worth buying, or that the market has mispriced it. A company can trade above or below its own historical range for years, and often does, for reasons the range knows nothing about.
The labels describe where today’s price falls against a calculated band. Nothing more than that.
Measured disagreement is our answer to a locked “uncertainty rating”: it is simply how far the estimators spread as a share of the midpoint, tiered Low / Moderate / High / Extreme, with the raw spread shown beside it. A wide band earns a high tier because the answer then depends heavily on which yardstick you pick — that is a finding, not a defect.
Filing health is computed separately and never looks at price. It reads the Piotroski F-Score, the Altman Z-Score and the Beneish M-Score straight from the filings: Sound means none of them flagged, Mixed means one moderate flag, Weak means a distress or manipulation flag, or several softer ones. For banks and insurers it reads Not assessed: all three scores were built on non-financial companies and their authors excluded financials, so for a balance-sheet business they measure the shape of the business rather than its health. Keeping the two axes apart is deliberate — a cheap company with weak filings is a very different object from a cheap company with sound ones, and a single blended verdict would hide which you are looking at.
Why some estimators are skipped. A multiple can be arithmetically computable and still meaningless. GAAP depreciation crushes REIT earnings, so we do not price a REIT off P/E; revenue and free cash flow are not comparable measures for a bank or an insurer, so those are dropped too. We would rather show you the estimators we trust and name every one we withheld, with the reason, than quietly fold in a number we do not believe.
Every number above is arithmetic you can redo. The inputs are INM’s own SEC filings and our price history; the formulas are stated on this page. There is no proprietary black box, and there is nothing here you have to take on trust. How often the band rates a stock, and what we have not measured.
This is a computed description of a security against a published formula — not investment advice, not a recommendation, and not a price target. Labels describe INM against the band above; they say nothing about whether it suits your circumstances. Historical multiples are not a forecast, and a company can stay outside its own historical range for years. Educational information only.
The fair-value line is INM’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from INM’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
Total return including reinvested dividends, from INM’s adjusted closing prices. Past return is not a forecast and not investment advice.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Group: Pharmaceutical Preparations, the SEC industry code INM files under. 10 companies in our stored table file under it.
| Metric | INM | Group median | 25th to 75th percentile | Where INM sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | not placed | 21.4%⊙INFERENCE — derived by arithmetic SourceNet margin across the 10 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure. | 13.0% to 28.4% | INM has no annual report in the stored table yet, so it has no figure to place. |
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | not placed | 20.9%⊙INFERENCE — derived by arithmetic SourceFree cash flow margin across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's operating cash flow less capital expenditure, divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 16.7% to 26.7% | INM has no annual report in the stored table yet, so it has no figure to place. |
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | not placed | 32.9%⊙INFERENCE — derived by arithmetic SourceReturn on equity across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by stockholders’ equity at the fiscal year end, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 12.5% to 38.2% | INM has no annual report in the stored table yet, so it has no figure to place. |
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Head office: Vancouver, BC, Canada
Source: the cover page of InMed Pharmaceuticals Inc.’s 10-Q filed 2026-11-03, on EDGAR. Filings checked 2026-11-10. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No tracked institution reported a position in INM in the latest 13F round.
| ADAR1 Capital Management, LLC10% owner | BUY | $35K | view → |
| ADAR1 Capital Management, LLC10% owner | BUY | $0K | view → |
| ADAR1 Capital Management, LLC10% owner | BUY | $1K | view → |
| ADAR1 Capital Management, LLC10% owner | BUY | $13K | view → |
| ADAR1 Capital Management, LLC10% owner | BUY | $14K | view → |
| ADAR1 Capital Management, LLC10% owner | BUY | $57K | view → |
| ADAR1 Capital Management, LLC10% owner | BUY | $118K | view → |
| ADAR1 Capital Management, LLC10% owner | BUY | $2K | view → |
No lawmaker has disclosed a trade in INM under the STOCK Act.